糖尿病前期市場：按治療/管理方式、性別、年齡層、銷售管道、體重類別、最終用戶和地區分類

2026年，糖尿病前期市場規模估計為95.4億美元，預計2033年將達到166.7億美元。預計從2026年到2033年，該市場將以8.3%的複合年成長率成長。

全球糖尿病前期市場是整個糖尿病管理生態系統中的關鍵組成部分，旨在應對日益普遍的葡萄糖耐受不良和高血糖症，領先。糖尿病前期的特徵是血糖值高於正常值，但尚未達到糖尿病診斷閾值，影響全球數百萬人口，並為介入預防其發展為完全糖尿病提供了重要契機。

該市場涵蓋專為糖尿病前期患者（BRAD）設計的診斷工具、治療性介入、監測設備和生活方式管理解決方案。肥胖率上升、久坐的生活方式以及人口老化導致BRAD盛行率不斷攀升，促使全球醫療保健系統優先考慮早期檢測和干涉策略。該市場的重要性不僅限於滿足眼前的醫療保健需求，還包括透過預防性醫療保健方法實現的長期成本節約。主要相關人員包括研發降血糖藥物的製藥公司、生產連續血糖監測系統的醫療設備製造商、提供篩檢測試的篩檢實驗室以及提供生活方式改善計畫的數位健康平台。 BRAD市場的演變反映了醫療保健產業向預防醫學的模式轉移，並強調透過早期檢測和管理血糖代謝紊亂來改善患者早期療育，同時減少糖尿病相關併發症和醫療保健成本。

市場動態

全球糖尿病前期市場正經歷強勁成長，這主要得益於多種相互關聯的因素共同推動市場擴張和創新。其中一個關鍵促進因素是全球糖尿病前期盛行率的激增。據估計，全球約有3.74億成年人存在葡萄糖耐受不良，導致對診斷和治療解決方案的需求顯著成長。此外，不斷加強的健康意識宣傳活動和政府主導的早期糖尿病篩檢措施也對市場成長做出了重要貢獻。非侵入式血糖監測設備和數位健康平台的進步，增強了病患參與度和監測能力，也促進了市場發展。然而，該市場也面臨許多限制因素，包括發展中地區醫療基礎設施不足、持續血糖監測系統高成本，以及許多醫療體系中糖尿病前期管理項目的保險覆蓋範圍有限。

此外，患者依從性方面的挑戰，例如生活方式改善和藥物依從性，仍然是市場滲透的障礙。儘管有這些限制，但透過開發針對糖尿病前期患者的個人化干預措施，並利用基因檢測和生物標記識別，正在湧現出巨大的機會。將人工智慧 (AI) 和機器學習整合到糖尿病風險評估的預測分析中，正在開闢新的市場可能性，而遠距遠端醫療能力的擴展和遠端患者監護解決方案的部署，正在幫助消除醫療保健服務的地域障礙。此外，製藥公司專注於開發特異性針對糖尿病前期人群的新療法，以及注重預防醫學的公司不斷擴大健康計劃，正在為糖尿病前期管理各個領域的相關人員創造更多市場機會。

本次調查的主要特點

• 本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
• 此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略的重要見解。
• 本研究根據以下參數創建了全球糖尿病前期市場主要公司的概況：公司亮點、產品系列、關鍵亮點、財務表現和策略。
• 透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
• 這份全球糖尿病前期市場報告的目標受群眾外包括產業內的各種相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
• 透過對全球糖尿病前期市場進行分析時所使用的各種策略矩陣，相關人員將能夠更輕鬆地做出決策。

目錄

第1章：研究目標與前提條件

• 分析目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要

第3章：市場動態、監管與趨勢分析

• 市場動態
• 促進因素
• 抑制因子
• 機會
• 影響分析
• 主要進展
• 監管趨勢
• 產品上市及核准
• PEST分析
• 波特的分析
• 併購情景
• 產業趨勢

第4章 全球糖尿病前期市場：依治療及管理方式分類，2021-2033年

• 二甲雙胍
• 數位健康和​​穿戴設備
• 血糖監測設備（CGM、BGM）
• 草藥補充劑
• 其他（益生菌和腸道健康產品等）

第5章 全球糖尿病前期市場：依性別分類，2021-2033年

• 男性
• 女士

第6章 全球糖尿病前期市場：依年齡層別分類，2021-2033年

• 成人
• 兒童

第7章 全球糖尿病前期市場：依通路分類，2021-2033年

• 線上
• 離線

第8章 全球糖尿病前期市場：依體重類別分類，2021-2033年

• 超重和肥胖人群（主要目標人群）
• 體重正常但有代謝風險（未確診部分）

第9章 全球糖尿病前期市場：依最終用戶分類，2021-2033年

• 醫院
• 診斷檢查室
• 居家醫療
• 專科診所
• 健康與健康中心

第10章 全球糖尿病前期市場：依地區分類，2021-2033年

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲國家
• 歐洲
  • 德國
  • 英國
  • 西班牙
  • 法國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • ASEAN
  • 其他亞太國家
• 中東
  • 海灣合作理事會國家
  • 以色列
  • 其他中東國家
• 非洲
  • 南非
  • 北非
  • 中非

第11章 競爭格局

• Bristol-Myers Squibb
• Mylan Pharmaceuticals
• Teva Pharmaceuticals
• Sun Pharmaceutical Industries
• Sandoz（Novartis）
• Glenmark
• Dexcom
• Abbott Laboratories
• Medtronic
• Ascensia Diabetes Care
• Senseonics
• Herbalife Nutrition
• Nestle Health Science
• Danone

第12章 分析師建議

• 機會分析
• 分析師意見
• Coherent Opportunity Map

第13章 參考文獻與調查方法

• 參考
• 調查方法
• 關於本公司

Prediabetes Market is estimated to be valued at USD 9.54 Bn in 2026 and is expected to reach USD 16.67 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.3% from 2026 to 2033.

The global prediabetes market represents a critical segment within the broader diabetes management ecosystem, addressing the growing prevalence of impaired glucose tolerance and elevated blood sugar levels that precede type 2 diabetes onset. Prediabetes, characterized by blood glucose levels higher than normal but not yet reaching diabetic thresholds, affects millions worldwide and serves as a crucial intervention window for preventing progression to full-blown diabetes.

The market encompasses diagnostic tools, therapeutic interventions, monitoring devices, and lifestyle management solutions specifically designed for prediabetic populations. With rising obesity rates, sedentary lifestyles, and aging demographics contributing to increased prediabetes prevalence, healthcare systems globally are prioritizing early detection and intervention strategies. The market's significance extends beyond immediate healthcare needs, encompassing long-term cost reduction through preventive care approaches. Key stakeholders include pharmaceutical companies developing glucose-lowering medications, medical device manufacturers creating continuous glucose monitoring systems, diagnostic laboratories offering screening tests, and digital health platforms providing lifestyle intervention programs. The prediabetes market's evolution reflects the healthcare industry's paradigm shift toward preventive medicine, emphasizing early intervention to reduce diabetes-related complications and healthcare expenditures while improving patient outcomes through timely identification and management of glucose metabolism disorders.

Market Dynamics

The global prediabetes market experiences robust growth, driven by several interconnected factors that collectively propel market expansion and innovation. Primary drivers include the escalating global prevalence of prediabetes, with an estimated 374 million adults worldwide living with impaired glucose tolerance, creating substantial demand for diagnostic and therapeutic solutions. Increasing healthcare awareness campaigns and government initiatives promoting early diabetes screening contribute significantly to market growth, as do technological advancements in non-invasive glucose monitoring devices and digital health platforms that enhance patient engagement and monitoring capabilities. However, the market faces notable restraints including limited healthcare infrastructure in developing regions, high costs associated with continuous glucose monitoring systems, and insufficient reimbursement coverage for prediabetes management programs in many healthcare systems.

Additionally, patient compliance challenges with lifestyle modifications and medication adherence present ongoing obstacles to market penetration. Despite these constraints, substantial opportunities emerge through the development of personalized medicine approaches utilizing genetic testing and biomarker identification for tailored prediabetes interventions. The integration of artificial intelligence and machine learning in predictive analytics for diabetes risk assessment opens new market avenues, while expanding telemedicine capabilities and remote patient monitoring solutions address geographical barriers to care access. Furthermore, pharmaceutical companies' increasing focus on developing novel therapeutic agents specifically targeting prediabetic populations, combined with growing corporate wellness programs emphasizing preventive healthcare, creates additional market opportunities for stakeholders across the prediabetes management spectrum.

Key Features of the Study

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global prediabetes market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Bristol-Myers Squibb, Mylan Pharmaceuticals, Teva Pharmaceuticals, Sun Pharmaceutical Industries, Sandoz (Novartis), Glenmark, Dexcom, Abbott Laboratories, Medtronic, Ascensia Diabetes Care, Senseonics, Herbalife Nutrition, Nestle Health Science, and Danone
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global prediabetes market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global prediabetes market

Market Segmentation

• Treatment & Management Insights (Revenue, USD Bn, 2021 - 2033)
• Metformin
• Digital Health and Wearables
• Glucose Monitoring Devices (CGM, BGM)
• Herbal Supplements
• Others (Probiotics and Gut Health Products, etc.)
• Gender Insights (Revenue, USD Bn, 2021 - 2033)
• Male
• Female
• Age Group Insights (Revenue, USD Bn, 2021 - 2033)
• Adult
• Pediatric
• Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
• Online
• Offline
• Specialty Pharmacies and Drugstores
• Supermarkets or Hypermarkets
• Weight Category Insights (Revenue, USD Bn, 2021 - 2033)
• Overweight and Obese Individuals (Primary Target)
• Normal Weight with Metabolic Risk (Underdiagnosed Segment)
• End User Insights (Revenue, USD Bn, 2021 - 2033)
• Hospitals
• Diagnostic Laboratories
• Home Care Settings
• Specialty Clinics
• Health and Wellness Centers
• Regional Insights (Revenue, USD Bn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
• Bristol-Myers Squibb
• Mylan Pharmaceuticals
• Teva Pharmaceuticals
• Sun Pharmaceutical Industries
• Sandoz (Novartis)
• Glenmark
• Dexcom
• Abbott Laboratories
• Medtronic
• Ascensia Diabetes Care
• Senseonics
• Herbalife Nutrition
• Nestle Health Science
• Danone

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Prediabetes Market, By Treatment & Management
  • Global Prediabetes Market, By Gender
  • Global Prediabetes Market, By Age Group
  • Global Prediabetes Market, By Distribution Channel
  • Global Prediabetes Market, By Weight Category
  • Global Prediabetes Market, By End User
  • Global Prediabetes Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Prediabetes Market, By Treatment & Management, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Metformin
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Digital Health and Wearables
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Glucose Monitoring Devices (CGM, BGM)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Herbal Supplements
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Others (Probiotics and Gut Health Products, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

5. Global Prediabetes Market, By Gender, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Male
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Female
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

6. Global Prediabetes Market, By Age Group, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Adult
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Pediatric
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

7. Global Prediabetes Market, By Distribution Channel, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Online
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Offline
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
    • Specialty Pharmacies and Drugstores
    • Supermarkets or Hypermarkets

8. Global Prediabetes Market, By Weight Category, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Overweight and Obese Individuals (Primary Target)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Normal Weight with Metabolic Risk (Underdiagnosed Segment)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

9. Global Prediabetes Market, By End User, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Diagnostic Laboratories
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Home Care Settings
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Specialty Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Health and Wellness Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

10. Global Prediabetes Market, By Region, 2021 - 2033, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Treatment & Management, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Weight Category, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Treatment & Management, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Weight Category, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Treatment & Management, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Weight Category, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Treatment & Management, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Weight Category, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Treatment & Management, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Weight Category, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Treatment & Management, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Weight Category, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

11. Competitive Landscape

• Bristol-Myers Squibb
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Mylan Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Teva Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sun Pharmaceutical Industries
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sandoz (Novartis)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Glenmark
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Dexcom
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Abbott Laboratories
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Medtronic
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Ascensia Diabetes Care
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Senseonics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Herbalife Nutrition
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Nestle Health Science
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Danone
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

12. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

13. References and Research Methodology

• References
• Research Methodology
• About us